Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
For full access to this article login to GEN Select now.
GEN Review BIO 2008: Grappling with the Regulation of Biosimilars
Preserving the Incentives for Innovation Remains a Key Concern for Biotech Firms
- The vast generic pharmaceutical product market is fertile ground for litigation as companies seek to defend hard-won patent protection for their compounds in the face of fierce biogeneric competition. In the past, standards of equivalency were fairly clear, but today, with the rise of biopharmaceuticals, regulatory agencies have a ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.